X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (23334) 23334
Publication (3985) 3985
Book Review (1795) 1795
Book Chapter (43) 43
Conference Proceeding (28) 28
Newspaper Article (27) 27
Dissertation (11) 11
Magazine Article (3) 3
Book / eBook (2) 2
Data Set (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22155) 22155
humans (16140) 16140
animals (10306) 10306
cell cycle (6649) 6649
mice (6170) 6170
cell biology (6002) 6002
female (5360) 5360
apoptosis (5320) 5320
phosphorylation (5276) 5276
oncology (4992) 4992
biochemistry & molecular biology (4982) 4982
cancer (4708) 4708
cell line, tumor (4568) 4568
male (4535) 4535
proteins (4344) 4344
expression (4331) 4331
cyclin-dependent kinases (3932) 3932
cell proliferation (3496) 3496
cyclin-dependent kinase inhibitor p21 - metabolism (3417) 3417
kinases (3314) 3314
gene expression (3308) 3308
cyclin-dependent kinases - metabolism (3222) 3222
tumor suppressor protein p53 - metabolism (2980) 2980
research (2911) 2911
signal transduction (2837) 2837
cyclin-dependent kinase inhibitor p21 (2694) 2694
cells, cultured (2404) 2404
p53 (2351) 2351
middle aged (2346) 2346
cyclins - metabolism (2197) 2197
apoptosis - drug effects (2177) 2177
article (2145) 2145
cell line (2129) 2129
analysis (2111) 2111
cell proliferation - drug effects (2105) 2105
activation (2099) 2099
immunohistochemistry (2084) 2084
cell cycle proteins - metabolism (2063) 2063
research article (2032) 2032
proliferation (2007) 2007
cyclin-dependent kinase inhibitor p21 - genetics (1964) 1964
mutation (1963) 1963
genetic aspects (1962) 1962
multidisciplinary sciences (1954) 1954
cyclin-dependent kinase inhibitor p16 - metabolism (1912) 1912
rats (1898) 1898
adult (1894) 1894
aged (1886) 1886
tumors (1819) 1819
blotting, western (1805) 1805
p21 (1755) 1755
gene expression regulation, neoplastic (1700) 1700
biology (1674) 1674
protein (1664) 1664
growth (1654) 1654
cyclin-dependent kinase inhibitor p27 - metabolism (1591) 1591
cell cycle - drug effects (1583) 1583
cell growth (1578) 1578
medicine (1574) 1574
cell-cycle (1570) 1570
protein binding (1559) 1559
physiological aspects (1558) 1558
cyclin-dependent kinase (1541) 1541
cells (1535) 1535
tumor suppressor protein p53 - genetics (1518) 1518
cyclin-dependent kinase inhibitor p27 (1484) 1484
genes (1473) 1473
gene-expression (1454) 1454
tumor cells, cultured (1428) 1428
protein-serine-threonine kinases - metabolism (1427) 1427
down-regulation (1425) 1425
cyclin-dependent kinase inhibitor p16 - genetics (1419) 1419
in-vivo (1413) 1413
genetics & heredity (1406) 1406
antineoplastic agents - pharmacology (1392) 1392
transfection (1377) 1377
cell division (1373) 1373
p27 (1370) 1370
gene (1368) 1368
inhibition (1327) 1327
health aspects (1311) 1311
differentiation (1308) 1308
dna damage (1289) 1289
molecular sequence data (1289) 1289
retinoblastoma protein - metabolism (1288) 1288
science (1287) 1287
dna (1258) 1258
pathology (1223) 1223
cyclin-dependent kinase 2 (1201) 1201
rna, messenger - metabolism (1199) 1199
time factors (1178) 1178
cyclin-dependent kinases - antagonists & inhibitors (1170) 1170
flow cytometry (1170) 1170
gene expression regulation (1167) 1167
mice, knockout (1167) 1167
cyclin d1 - metabolism (1159) 1159
in-vitro (1158) 1158
prognosis (1131) 1131
cell cycle - physiology (1130) 1130
up-regulation (1127) 1127
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (23211) 23211
Chinese (134) 134
Russian (11) 11
Japanese (8) 8
German (4) 4
French (3) 3
Spanish (2) 2
Czech (1) 1
Korean (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Cell, ISSN 1097-2765, 01/2014, Volume 53, Issue 2, pp. 193 - 208
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 06/2017, Volume 546, Issue 7658, pp. 426 - 430
D-type cyclins (D1, D2 and D3) and their associated cyclin-dependent kinases (CDK4 and CDK6) are components of the core cell cycle machinery that drives cell... 
FLUX ANALYSIS | SITE | CATABOLISM | PYRUVATE-KINASE | GLUTAMINE | PHOSPHOFRUCTOKINASES | MULTIDISCIPLINARY SCIENCES | CDK4/6 INHIBITION | PROTEIN-PHOSPHORYLATION | CONFIDENCE | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Neoplasms - metabolism | Pentose Phosphate Pathway - drug effects | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Reactive Oxygen Species - metabolism | Apoptosis - drug effects | Humans | Glycolysis - drug effects | Aminopyridines - therapeutic use | Female | Purines - therapeutic use | Phosphorylation - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - metabolism | Cyclin D3 - metabolism | Cell Survival - drug effects | Pyruvate Kinase - metabolism | Purines - pharmacology | Reactive Nitrogen Species - metabolism | Neoplasms - enzymology | Cyclin-Dependent Kinase 6 - metabolism | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - enzymology | Cyclin-Dependent Kinase 4 - metabolism | Serine - metabolism | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Animals | Aminopyridines - pharmacology | Cell Line, Tumor | Mice | Oxidative Stress - drug effects | Cell Cycle - drug effects | Neoplasms - pathology | Phosphofructokinase-1 - metabolism | Phosphates | Reactive oxygen species | Phosphorylation | Brain cancer | Clinical trials | Catalytic activity | Kinases | Cyclin-dependent kinase 6 | Machinery | Cyclin-dependent kinase 4 | Cyclin D3 | Proteins | Antioxidants | Pathways | Metabolites | Pentose | Xenografts | Cell cycle | Inhibition | NADP | Cyclin D | Catalysis | Phosphofructokinase | Glutathione | Pentose phosphate | Enzymes | Medical research | Oxygen | Cell survival | Pyruvate kinase | Cyclin-dependent kinases | Metabolism | Survival | Cyclins | Intermediates | Cell death | Glycolysis | Scientific imaging | Mass spectrometry | Tumors | Apoptosis | Cancer | 6-Phosphofructokinase | Index Medicus
Journal Article
BMC Cancer, ISSN 1471-2407, 01/2014, Volume 14, Issue 1, pp. 32 - 32
Background: Although MYC is an attractive therapeutic target for breast cancer treatment, it has proven challenging to inhibit MYC directly, and clinically... 
Cyclin-dependent kinase | Breast cancer | Synthetic lethality | MYC | SYNTHETIC LETHAL | C-MYC | TUMOR-CELLS | PROLIFERATION | INHIBITION | GENE | ONCOLOGY | PATHWAY | ESTROGEN | THERAPEUTIC TARGETS | EXPRESSION | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Phosphorylation | Cyclin-Dependent Kinase 4 - genetics | Humans | Molecular Targeted Therapy | CDC2 Protein Kinase - metabolism | Dose-Response Relationship, Drug | Breast Neoplasms - enzymology | Transfection | Bcl-2-Like Protein 11 | RNA Interference | Female | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Cell Death - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Proto-Oncogene Proteins - metabolism | Cyclin-Dependent Kinase 2 - metabolism | CDC2 Protein Kinase - genetics | CDC2 Protein Kinase - antagonists & inhibitors | Cyclin-Dependent Kinase 6 - genetics | Tumor Suppressor Protein p53 - metabolism | Cyclin-Dependent Kinase 2 - genetics | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Proto-Oncogene Proteins c-myc - metabolism | Apoptosis Regulatory Proteins - metabolism | Breast Neoplasms - genetics | Signal Transduction - drug effects | Breast Neoplasms - pathology | Cell Cycle Checkpoints - drug effects | Cell Line, Tumor | Cyclin-Dependent Kinase 2 - antagonists & inhibitors | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Proto-Oncogene Proteins c-myc - genetics | Care and treatment | Patient outcomes | Cancer cells | Physiological aspects | Genetic aspects | Research | Risk factors | Cyclins | Index Medicus
Journal Article
Cancer Cell, ISSN 1535-6108, 03/2016, Volume 29, Issue 3, pp. 255 - 269
Journal Article
Cancer Cell, ISSN 1535-6108, 07/2014, Volume 26, Issue 1, pp. 136 - 149
Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast cancer. However, clinical results of single-agent PI3K inhibitors have... 
DRUG | INACTIVATION | ADVANCED SOLID TUMORS | MAMMARY-TUMORS | GENE | ONCOLOGY | PATHWAY INHIBITORS | CYCLIN D1 EXPRESSION | GROWTH | PHASE-I | PRECLINICAL EVALUATION | CELL BIOLOGY | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Phosphorylation | Phosphatidylinositol Phosphates - metabolism | Cyclin-Dependent Kinase 4 - genetics | Humans | Drug Resistance, Neoplasm | Phosphatidylinositol 3-Kinases - metabolism | Molecular Targeted Therapy | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Breast Neoplasms - enzymology | Transfection | MCF-7 Cells | RNA Interference | Time Factors | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - metabolism | Cell Survival - drug effects | Genetic Predisposition to Disease | Retinoblastoma Protein - metabolism | Cyclin-Dependent Kinase 6 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Mice, SCID | Breast Neoplasms - drug therapy | Drug Synergism | Phosphatidylinositol 3-Kinases - genetics | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Phenotype | Animals | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Signal Transduction - drug effects | Breast Neoplasms - pathology | Mice, Nude | Cell Proliferation - drug effects | Mice | Mutation | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Medical colleges | Breast cancer | Index Medicus
Journal Article
Oncogene, ISSN 0950-9232, 06/2017, Volume 36, Issue 23, pp. 3334 - 3345
Despite remarkable progress in cutaneous melanoma genomic profiling, the mutational landscape of primary mucosal melanomas (PMM) remains unclear. Forty-six... 
TARGETED THERAPY | MUTANT MELANOMA | BIOCHEMISTRY & MOLECULAR BIOLOGY | IMPROVED SURVIVAL | CANCER | CELL BIOLOGY | MUTATED MELANOMA | GENE FUSIONS | MEK INHIBITION | ONCOLOGY | GENETICS & HEREDITY | RAF INHIBITORS | MUTATIONS | SEQUENCING DATA | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Oncogene Proteins, Fusion - metabolism | Skin Neoplasms - drug therapy | Apoptosis - drug effects | Cyclin-Dependent Kinase 4 - genetics | Humans | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | MAP Kinase Kinase 1 - genetics | Biomarkers, Tumor - metabolism | Female | Antineoplastic Agents - pharmacology | Mucous Membrane - drug effects | Tumor Cells, Cultured | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - metabolism | Melanoma - metabolism | Skin Neoplasms - pathology | MAP Kinase Kinase 1 - antagonists & inhibitors | Cyclin-Dependent Kinase 6 - genetics | MAP Kinase Kinase 1 - metabolism | Cyclin-Dependent Kinase 6 - metabolism | Melanoma - pathology | Transcription Factors - genetics | Cyclin-Dependent Kinase 4 - metabolism | Mucous Membrane - metabolism | Skin Neoplasms - metabolism | Phosphatidylinositol 3-Kinases - genetics | Transcription Factors - metabolism | Xenograft Model Antitumor Assays | Mucous Membrane - pathology | Animals | Mice, Nude | Oncogene Proteins, Fusion - genetics | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Mice | Mitogen-Activated Protein Kinases - metabolism | Care and treatment | Gene mutations | Melanoma | Development and progression | Cellular signal transduction | Genetic aspects | Health aspects | Index Medicus
Journal Article
Nature Communications, ISSN 2041-1723, 06/2017, Volume 8, Issue 1, pp. 15916 - 15916
Deregulation of the cell cycle machinery is a hallmark of cancer. While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen... 
PALBOCICLIB | APOPTOSIS | CELLS | OXIDATIVE STRESS | ADVANCED BREAST-CANCER | MULTIDISCIPLINARY SCIENCES | REGULATES AUTOPHAGY | LETROZOLE | G1 ARREST | DEPENDENT KINASE INHIBITOR | ANTITUMOR-ACTIVITY | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Cyclin-Dependent Kinase 4 - genetics | Humans | Cellular Senescence - drug effects | Cytoplasm - metabolism | Antineoplastic Agents - administration & dosage | Breast Neoplasms - physiopathology | Cyclin E - genetics | Autophagy - drug effects | Breast Neoplasms - metabolism | Female | Cytoplasm - genetics | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - administration & dosage | Retinoblastoma Protein - metabolism | Cyclin-Dependent Kinase 6 - genetics | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Drug Synergism | Protein Kinase Inhibitors - administration & dosage | Animals | Breast Neoplasms - genetics | Mice, Nude | Retinoblastoma Protein - genetics | Cell Line, Tumor | Mice | Cyclin E - metabolism | Cell Cycle - drug effects | Cytoplasm - drug effects | Senescence | Deregulation | Estrogens | Estrogen | Estrogen receptors | Breast cancer | In vitro testing | Autophagy | Machinery | Cyclin-dependent kinase 4 | Inhibitors | Cell cycle | Xenografts | Biomarkers | Breast | Cyclin E | Bioindicators | Inhibition | Phagocytosis | Tumors | Cancer | Index Medicus
Journal Article
Breast Cancer Research, ISSN 1465-5411, 10/2009, Volume 11, Issue 5, pp. R77 - R77
Journal Article
Journal Article
Hepatology, ISSN 0270-9139, 12/2017, Volume 66, Issue 6, pp. 1952 - 1967